Merck and Moderna Vaccine Cuts Melanoma Recurrence Risk 42%

Merck and Moderna reported that a personalized mRNA vaccine, given alongside immunotherapy, reduced the risk of melanoma recurrence or death by 42 percent compared with immunotherapy alone, according to Phase 3 trial results detailed by Wired.

The trial, called INTerpath-001, enrolled 1,137 people with high-risk melanoma who had already undergone surgery to remove their tumors. Researchers split participants into two groups and followed them for an average of 24.6 months.

What did the INTerpath-001 trial measure?

One group received only pembrolizumab, an immunotherapy drug marketed to help the immune system identify and attack cancer cells. The second group received pembrolizumab plus the experimental vaccine, known as intismeran autogene. The study was designed to compare recurrence, spread, and survival between the two groups rather than to test the vaccine as a standalone treatment.

How large was the reduction in recurrence risk?

Researchers found that adding the vaccine lowered the risk of recurrence or death by 42 percent relative to pembrolizumab alone. The combination also cut the risk of the cancer spreading to other parts of the body by 38 percent, Wired reported. At the close of the follow-up period:

• 82.2 percent of patients who received both the vaccine and pembrolizumab remained recurrence-free.
• 70 percent of patients who received pembrolizumab alone remained recurrence-free.

Those figures represent a roughly 12-percentage-point gap between the two groups after more than two years of monitoring, though the trial's design means longer follow-up will be needed to confirm whether the gap holds or widens.

How is each patient's vaccine made?

The vaccine is not off-the-shelf. According to the companies, researchers sequence a tumor sample taken from each patient to identify mutations specific to that person's cancer. From those mutations, scientists select up to three molecular signatures believed to trigger an immune response, then manufacture an individualized mRNA vaccine designed to teach the immune system to recognize and attack cells carrying those markers. The approach mirrors earlier-stage mRNA cancer vaccine work but is now backed by Phase 3 data, a step beyond the smaller trials that preceded it.

"These results are transformative and have the potential to make a foundational shift in how we treat patients with earlier-stage melanoma," said Georgina Long, medical director of the Australian Melanoma Institute and the study's principal investigator, in a statement cited by Wired.

What side effects emerged during the trial?

Participants who received the vaccine reported mild side effects, including fever, fatigue, and pain at the injection site, consistent with safety signals observed in earlier trials of the same vaccine. Wired's report did not describe any severe or unexpected adverse events tied specifically to the combination therapy, and the companies said the Phase 3 results point to a similar safety profile to what was seen before pembrolizumab was added.

What happens next for FDA approval?

The vaccine has not yet received regulatory clearance. Wired reported that intismeran autogene is still awaiting approval from the Food and Drug Administration, meaning the combination treatment is not yet available to patients outside clinical trial settings. No timeline for a regulatory decision was included in the available reporting.

What do outside researchers say about the findings?

Eva Muñoz Couselo, who leads a melanoma research group at the Vall d'Hebron Institute of Oncology in Barcelona and was not involved in the study, told SMC Spain that the trial marks a notable moment for personalized cancer treatment. "The results of the INTerpath-001 study represent a major breakthrough in the treatment of melanoma and, in particular, in the development of personalized medicine," she said, according to Wired's account of her comments. "For the first time, a Phase III trial has demonstrated that an individualized therapeutic vaccine, designed on the basis of the molecular characteristics of each patient's tumor, can significantly improve the outcomes of conventional immunotherapy."

Her assessment, offered as an outside observer rather than a trial investigator, underscores why researchers are treating the Phase 3 data as a signal worth watching rather than a settled verdict — the sample size of 1,137 patients and roughly two-year follow-up window leave open questions about durability that only longer-term data, and eventually regulatory review, can answer.

Artiglio is A coming-soon iPhone chief of staff for briefings and drafts. Not on the App Store yet.